Poxel S.A. (POXEL.PA)
EUR 0.13
(-0.94%)
EUR 0.13
(-0.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.17 Million EUR | 43.62% |
| 2022 | -28.02 Million EUR | -2.45% |
| 2021 | -22.52 Million EUR | 31.76% |
| 2020 | -29.71 Million EUR | -27.83% |
| 2019 | -24.59 Million EUR | -291.73% |
| 2018 | -2.8 Million EUR | 156.73% |
| 2017 | -21.86 Million EUR | 7.33% |
| 2016 | -23.15 Million EUR | -108.71% |
| 2015 | -11.31 Million EUR | 15.71% |
| 2014 | -15.64 Million EUR | -87.76% |
| 2013 | -23.31 Million EUR | -2.16% |
| 2012 | -9.4 Million EUR | 18.04% |
| 2011 | -11.31 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - EUR | 109.18% |
| 2023 Q4 | 1.02 Million EUR | 0.0% |
| 2023 Q2 | 16.57 Million EUR | 0.0% |
| 2022 FY | - EUR | -2.45% |
| 2022 Q4 | -9.99 Million EUR | 0.0% |
| 2022 Q2 | -654 Thousand EUR | 0.0% |
| 2021 FY | - EUR | 31.76% |
| 2021 Q2 | -8.13 Million EUR | 0.0% |
| 2021 Q4 | -16.15 Million EUR | 0.0% |
| 2020 Q2 | -13.41 Million EUR | 0.0% |
| 2020 FY | - EUR | -27.83% |
| 2020 Q4 | -18.39 Million EUR | 0.0% |
| 2019 FY | - EUR | -291.73% |
| 2019 Q1 | -6.28 Million EUR | -3.77% |
| 2019 Q2 | -7.24 Million EUR | -15.27% |
| 2019 Q4 | -21.37 Million EUR | 0.0% |
| 2018 FY | - EUR | 156.73% |
| 2018 Q4 | -6.05 Million EUR | 0.0% |
| 2018 Q1 | 3.41 Million EUR | 127.61% |
| 2018 Q2 | 6.43 Million EUR | 88.23% |
| 2017 Q2 | -9.49 Million EUR | -70.92% |
| 2017 FY | - EUR | 7.33% |
| 2017 Q4 | -12.37 Million EUR | 0.0% |
| 2017 Q1 | -5.55 Million EUR | 49.4% |
| 2016 Q1 | -5.99 Million EUR | 4.61% |
| 2016 Q4 | -10.97 Million EUR | 0.0% |
| 2016 FY | - EUR | -108.71% |
| 2016 Q2 | -12.17 Million EUR | -103.15% |
| 2015 Q2 | -5.03 Million EUR | -77.14% |
| 2015 FY | - EUR | 15.71% |
| 2015 Q4 | -6.28 Million EUR | -121.19% |
| 2015 Q3 | -2.84 Million EUR | 43.55% |
| 2015 Q1 | -2.84 Million EUR | 9.35% |
| 2014 Q4 | -3.13 Million EUR | 8.51% |
| 2014 Q3 | -3.42 Million EUR | 8.69% |
| 2014 Q2 | -3.75 Million EUR | -9.52% |
| 2014 Q1 | -3.42 Million EUR | 24.77% |
| 2014 FY | - EUR | -87.76% |
| 2013 FY | - EUR | -2.16% |
| 2013 Q4 | -4.55 Million EUR | 10.91% |
| 2013 Q2 | -2.7 Million EUR | 47.02% |
| 2013 Q3 | -5.1 Million EUR | -88.74% |
| 2013 Q1 | -5.1 Million EUR | 0.0% |
| 2012 Q3 | -1.78 Million EUR | 0.0% |
| 2012 FY | - EUR | 18.04% |
| 2012 Q1 | -1.78 Million EUR | 0.0% |
| 2012 Q2 | -1.78 Million EUR | 0.0% |
| 2012 Q4 | -5.1 Million EUR | -186.92% |
| 2011 Q2 | -2.15 Million EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q1 | -2.15 Million EUR | 0.0% |
| 2011 Q4 | -1.78 Million EUR | 17.27% |
| 2011 Q3 | -2.15 Million EUR | 0.0% |
| 2010 Q4 | -2.15 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -270.182% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 90.857% |
| Adocia SA | -22.73 Million EUR | 46.424% |
| Aelis Farma SA | -6.34 Million EUR | -91.886% |
| Biophytis S.A. | -13.8 Million EUR | 11.772% |
| Advicenne S.A. | -6.24 Million EUR | -95.051% |
| genOway Société anonyme | 6.35 Million EUR | 291.773% |
| IntegraGen SA | -52.5 Thousand EUR | -23096.77% |
| Medesis Pharma S.A. | -3.84 Million EUR | -216.759% |
| Neovacs S.A. | -8.44 Million EUR | -44.138% |
| NFL Biosciences SA | -4.04 Million EUR | -200.768% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 16891.672% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -323.841% |
| Sensorion SA | -22.31 Million EUR | 45.419% |
| Theranexus Société Anonyme | -7.38 Million EUR | -64.866% |
| TME Pharma N.V. | -5.07 Million EUR | -140.122% |
| Valbiotis SA | -6.95 Million EUR | -75.111% |
| TheraVet SA | -517.33 Thousand EUR | -2254.176% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 35.615% |
| argenx SE | -199.5 Million EUR | 93.895% |
| BioSenic S.A. | -6.79 Million EUR | -79.208% |
| Celyad Oncology SA | -7.76 Million EUR | -56.885% |
| DBV Technologies S.A. | -79.53 Million EUR | 84.686% |
| Galapagos NV | 51.03 Million EUR | 123.863% |
| Genfit S.A. | -28.05 Million EUR | 56.583% |
| GeNeuro SA | -14.31 Million EUR | 14.937% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 18.698% |
| Innate Pharma S.A. | -7.57 Million EUR | -60.715% |
| Inventiva S.A. | -101.84 Million EUR | 88.042% |
| MaaT Pharma SA | -19.74 Million EUR | 38.303% |
| MedinCell S.A. | -20.04 Million EUR | 39.245% |
| Nanobiotix S.A. | -34.01 Million EUR | 64.199% |
| Onward Medical N.V. | -35.23 Million EUR | 65.434% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -174.713% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 47.653% |
| Oxurion NV | -16.72 Million EUR | 27.198% |
| Pharming Group N.V. | 4.98 Million EUR | 344.511% |
| GenSight Biologics S.A. | -21.73 Million EUR | 43.953% |
| Transgene SA | -27.02 Million EUR | 54.933% |
| Financière de Tubize SA | 184.57 Thousand EUR | 6698.545% |
| UCB SA | 1.26 Billion EUR | 100.96% |
| Valneva SE | -64.51 Million EUR | 81.123% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 57.045% |